Document is current

Article History

Received: 15 December 2025

Accepted: 7 May 2026

First Online: 16 May 2026

Declarations

:

: This study belongs to the MAB Registry and includes participants from phase IV clinical trials EudraCT Number: 2019-002224-32, REEC ID: 2020-002639-31, and REEC ID: 2020-003650-77, and was approved by the Vall d’Hebron Ethics Committee (PR(AG)53/2017). All patients provided written informed consent that was obtained according to the Declaration of Helsinki.

: Not applicable.

: In relation to this paper, the authors declared the following potential conflicts of interest: JR-M has nothing to disclose. EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape, Lilly, Organon, Teva and Dr. Reddy’s; his salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065). He is a junior editor for Cephalalgia. VJG has nothing to disclose. DP has nothing to disclose. AA has received honoraria from Allergan-AbbVie, Novartis, Chiesi. MT-F has received honoraria from Allergan-AbbVie, Novartis, Chiesi and Teva. EG-C has received honoraria for participation in medical education activities from AbbVie, Eli Lilly, Organon, Novartis, Teva, Lundbeck and Dr Reddy’s. Additionally, the author has received consulting fees from AbbVie, and Lundbeck. EG-C has also received research grants from Sociedad Española de Enfermería Neurológica. AR serves/ed on scientific advisory boards for Novartis, Sanofi-Genzyme, Synthetic MR, TensorMedical, Roche, and Biogen, and has received speaker honoraria from Bayer, Sanofi-Genzyme, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, Bristol-Myers and Biogen, is CMO and co-founder of TensorMedical, and receives research support from Fondo de Investigación en Salud (PI19/00950 and PI22/01589) from Instituto de Salud Carlos III, Spain. PP-R has received honoraria in the last 3 years, as a consultant and speaker from AbbVie, Almirall, Dr. Reddy’s, Eli Lilly, Lundbeck, Medscape, Organon, Pfizer, Novartis and Teva Pharmaceuticals. Her research group has received research grants from AbbVie, AGAUR, EraNET Neuron, FEDER RIS3CAT, Instituto Investigación Carlos III, MICINN, PERIS; and has received funding for clinical trials from AbbVie, Amgen, Biohaven, Eli Lilly, Ipsen, Lundbeck, Novartis, Pfizer, and Teva. PP-R does not own stocks from any pharmaceutical company.